Anavex Life Sciences Corp AVXL:NASDAQ

RT Quote | Last NYSE Arca, VOL From CTA | USD
after hours iconAfter Hours: Last | 07/01/22 EDT
10.81quote price arrow up+0.51 (+4.95%)
Volume
11,142
Close
10.30quote price arrow up+0.29 (+2.90%)
Volume
624,127
52 week range
7.13 - 28.26
Loading...
  • Open10.01
  • Day High10.33
  • Day Low9.93
  • Prev Close10.01
  • 52 Week High28.26
  • 52 Week High Date07/09/21
  • 52 Week Low7.13
  • 52 Week Low Date05/12/22

Key Stats

  • Market Cap797.32M
  • Shares Out77.41M
  • 10 Day Average Volume1.19M
  • Dividend-
  • Dividend Yield-
  • Beta0.81
  • YTD % Change-40.6

KEY STATS

  • Open10.01
  • Day High10.33
  • Day Low9.93
  • Prev Close10.01
  • 52 Week High28.26
  • 52 Week High Date07/09/21
  • 52 Week Low7.13
  • 52 Week Low Date05/12/22
  • Market Cap797.32M
  • Shares Out77.41M
  • 10 Day Average Volume1.19M
  • Dividend-
  • Dividend Yield-
  • Beta0.81
  • YTD % Change-40.6

RATIOS/PROFITABILITY

  • EPS (TTM)-0.58
  • P/E (TTM)-17.79
  • Fwd P/E (NTM)-14.78
  • EBITDA (TTM)-46.894M
  • ROE (TTM)-37.91%
  • Revenue (TTM)0.00
  • Gross Margin (TTM)-
  • Net Margin (TTM)-
  • Debt To Equity (MRQ)0.00%

EVENTS

  • Earnings Date08/10/2022(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Anavex Life Sciences Corp

There is no recent news for this security.

Content From Our Affiliates

Profile

MORE
Anavex Life Sciences Corp. is a clinical-stage biopharmaceutical company. The Company is engaged in the development of differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders. The Company’s lead compound ANAVEX2-73 is being developed to treat Alzheimer’s disease, Parkinson’s disease, and other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder caused by...
Christopher Missling Ph.D.
Chairman of the Board, President, Chief Executive Officer, Company Secretary
Sandra Boenisch CPA
Principal Financial Officer, Treasurer
Address
7TH FLOOR, 51 W 52ND STREET,
New York, NY
10019-6163
United States

Top Peers

SYMBOLLASTCHG%CHG
DSGN
Design Therapeutics Inc
14.09+0.09+0.64%
PHVS
Pharvaris NV
23.65+1.55+7.01%
VERV
Verve Therapeutics Inc
15.63+0.35+2.29%
RNA
Avidity Biosciences Inc
15.46+0.93+6.40%
REPL
Replimune Group Inc
18.38+0.90+5.15%